PPAR-gamma agonists in type 2 diabetes resulted in lower serum levels of pro-inflammatory markers, such as CRP, white blood cells, soluble CD40, MMP-9, amyloid A, and TNFα [15]. The gene discussed is PPARG; the disease is type 2 diabetes mellitus.